​

Orchestra BioMed (OBIO) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

OBIO Stock Forecast

Orchestra BioMed (OBIO) stock forecast, based on 4 Wall Street analysts, predicts a 12-month average price target of $12.00, with a high of $12.00 and a low of $12.00. This represents a 189.16% increase from the last price of $4.15.

$4 $5 $6 $7 $8 $9 $10 $11 $12 High: $12 Avg: $12 Low: $12 Last Closed Price: $4.15

OBIO Stock Rating

Orchestra BioMed stock's rating consensus is Buy, based on 4 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 3 Buy (75.00%), 1 Hold (25.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 4 0 1 3 Strong Sell Sell Hold Buy Strong Buy

OBIO Price Target Upside V Benchmarks

TypeNameUpside
StockOrchestra BioMed189.16%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts--1
Avg Price Target--$12.00
Last Closing Price$4.15$4.15$4.15
Upside/Downside--189.16%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Dec, 25241--7
Nov, 25331--7
Oct, 25331--7
Sep, 25331--7
Aug, 2534---7
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Mar 20, 2025Marie ThibaultBTIG$12.00$4.35175.86%189.16%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Dec 10, 2025Cowen & Co.Buyinitialise
Sep 04, 2025H.C. WainwrightBuyBuyhold
Apr 23, 2025H.C. WainwrightBuyBuyhold
Mar 20, 2025BTIGBuyinitialise
Jan 02, 2025BarclaysOverweightinitialise
Aug 22, 2024H.C. WainwrightBuyinitialise
Jul 24, 2024B. RileyBuyinitialise

Financial Forecast

EPS Forecast

$-20 $-16 $-12 $-8 $-4 $0 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.24$-1.48-----
Avg Forecast$-13.86$-1.48$-1.66$-1.92$-1.72$-1.66$-0.99
High Forecast$-9.43$-1.44$-1.65$-1.69$-1.06$-1.03$-0.61
Low Forecast$-18.00$-1.51$-1.67$-2.06$-2.39$-2.31$-1.38
Surprise %-83.84%------

Revenue Forecast

$0 $8M $16M $24M $32M $40M Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$3.53M$2.76M$2.64M----
Avg Forecast$4.30M$3.53M$3.19M$3.84M$3.89M$4.02M$27.27M
High Forecast$5.29M$4.33M$3.37M$5.01M$5.07M$5.24M$35.49M
Low Forecast$3.25M$2.72M$2.78M$2.71M$2.75M$2.84M$19.25M
Surprise %-17.93%-21.78%-17.24%----

Net Income Forecast

$-600M $-480M $-360M $-240M $-120M $0 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-33.61M$-49.12M$-61.02M----
Avg Forecast$-460.50M$-49.12M$-55.12M$-62.30M$-69.45M$-64.38M$-32.89M
High Forecast$-313.17M$-47.95M$-54.78M$-56.25M$-35.23M$-34.06M$-20.31M
Low Forecast$-598.07M$-50.25M$-55.45M$-68.35M$-79.40M$-76.78M$-45.79M
Surprise %-92.70%-10.72%----

OBIO Forecast FAQ

Is Orchestra BioMed stock a buy?

Orchestra BioMed stock has a consensus rating of Buy, based on 4 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 3 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Orchestra BioMed is a favorable investment for most analysts.

What is Orchestra BioMed's price target?

Orchestra BioMed's price target, set by 4 Wall Street analysts, averages $12 over the next 12 months. The price target range spans from $12 at the low end to $12 at the high end, suggesting a potential 189.16% change from the previous closing price of $4.15.

How does Orchestra BioMed stock forecast compare to its benchmarks?

Orchestra BioMed's stock forecast shows a 189.16% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Orchestra BioMed over the past three months?

  • December 2025: 28.57% Strong Buy, 57.14% Buy, 14.29% Hold, 0% Sell, 0% Strong Sell.
  • November 2025: 42.86% Strong Buy, 42.86% Buy, 14.29% Hold, 0% Sell, 0% Strong Sell.
  • October 2025: 42.86% Strong Buy, 42.86% Buy, 14.29% Hold, 0% Sell, 0% Strong Sell.

What is Orchestra BioMed’s EPS forecast?

Orchestra BioMed's average annual EPS forecast for its fiscal year ending in December 2025 is $-1.92, marking a 0% decrease from the reported $0 in 2024. Estimates for the following years are $-1.72 in 2026, $-1.66 in 2027, and $-0.99 in 2028.

What is Orchestra BioMed’s revenue forecast?

Orchestra BioMed's average annual revenue forecast for its fiscal year ending in December 2025 is $3.84M, reflecting a 45.73% increase from the reported $2.64M in 2024. The forecast for 2026 is $3.89M, followed by $4.02M for 2027, and $27.27M for 2028.

What is Orchestra BioMed’s net income forecast?

Orchestra BioMed's net income forecast for the fiscal year ending in December 2025 stands at $-62.3M, representing an 2.09% increase from the reported $-61.024M in 2024. Projections indicate $-69.451M in 2026, $-64.384M in 2027, and $-32.893M in 2028.